| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
|
N Engl J Med
|
2000
|
16.20
|
|
2
|
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
|
Lancet
|
1999
|
11.92
|
|
3
|
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).
|
Arthritis Rheum
|
2001
|
3.15
|
|
4
|
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
|
Arthritis Rheum
|
2004
|
3.00
|
|
5
|
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
|
Ann Rheum Dis
|
2008
|
2.45
|
|
6
|
Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus.
|
Arthritis Rheum
|
1998
|
1.96
|
|
7
|
Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.
|
Arthritis Rheum
|
1998
|
1.93
|
|
8
|
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review.
|
Arthritis Rheum
|
1997
|
1.92
|
|
9
|
Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype.
|
Arthritis Rheum
|
2005
|
1.58
|
|
10
|
Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States.
|
Lupus
|
2002
|
1.55
|
|
11
|
Infliximab in active early rheumatoid arthritis.
|
Ann Rheum Dis
|
2004
|
1.47
|
|
12
|
Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
|
J Rheumatol
|
2000
|
1.33
|
|
13
|
Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.
|
Arthritis Rheum
|
1995
|
1.20
|
|
14
|
Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.
|
Ann Intern Med
|
1997
|
1.18
|
|
15
|
Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis.
|
Arch Intern Med
|
1985
|
1.13
|
|
16
|
Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
|
Ann Rheum Dis
|
2008
|
1.03
|
|
17
|
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
|
Br J Rheumatol
|
1996
|
1.01
|
|
18
|
Progress in the treatment of rheumatoid arthritis.
|
JAMA
|
2001
|
1.01
|
|
19
|
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
|
Arthritis Rheumatol
|
2014
|
0.99
|
|
20
|
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
|
Arthritis Rheum
|
2013
|
0.98
|
|
21
|
Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD.
|
J Rheumatol
|
1999
|
0.97
|
|
22
|
Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States.
|
Ann Rheum Dis
|
2004
|
0.96
|
|
23
|
Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome.
|
Am J Med
|
1987
|
0.95
|
|
24
|
Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection.
|
Arthritis Rheum
|
1995
|
0.93
|
|
25
|
Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2).
|
Arthritis Rheum
|
1998
|
0.90
|
|
26
|
Systemic lupus erythematosus. Diagnosis and treatment.
|
Med Clin North Am
|
1997
|
0.87
|
|
27
|
Nitric oxide--friend or foe in arthritis?
|
J Rheumatol
|
1998
|
0.87
|
|
28
|
CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States.
|
Lupus
|
2004
|
0.86
|
|
29
|
Therapeutic approaches to the treatment of rheumatoid disease.
|
Med Clin North Am
|
1986
|
0.83
|
|
30
|
Self-efficacy for exercise, more than disease-related factors, is associated with objectively assessed exercise time and sedentary behaviour in rheumatoid arthritis.
|
Scand J Rheumatol
|
2014
|
0.82
|
|
31
|
Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus.
|
J Rheumatol
|
2001
|
0.82
|
|
32
|
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.
|
Arthritis Rheum
|
1996
|
0.81
|
|
33
|
A case of sustained massive gabapentin overdose without serious side effects.
|
Ther Drug Monit
|
1999
|
0.81
|
|
34
|
Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
|
Clin Nephrol
|
1996
|
0.80
|
|
35
|
The anti-La response of a single MRL/Mp-lpr/lpr mouse: specificity for DNA and VH gene usage.
|
Eur J Immunol
|
1994
|
0.77
|
|
36
|
The use of analgesics in the management of pain in rheumatic diseases.
|
Rheum Dis Clin North Am
|
1999
|
0.77
|
|
37
|
Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.
|
Clin Exp Rheumatol
|
2009
|
0.76
|
|
38
|
Bedside science reduces laboratory art.
|
Circulation
|
1995
|
0.75
|
|
39
|
Serum levels of soluble CD44 in primary Sjögren's syndrome.
|
J Rheumatol
|
2000
|
0.75
|
|
40
|
Radiographic joint damage in rheumatoid arthritis: a community-based perspective.
|
Arthritis Rheum
|
2001
|
0.75
|
|
41
|
Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature.
|
Semin Arthritis Rheum
|
1998
|
0.75
|
|
42
|
Presentation of multicentric Castleman's disease with sicca syndrome, cardiomyopathy, palmar and plantar rash.
|
J Rheumatol
|
1993
|
0.75
|
|
43
|
An unusual photoactivated skin eruption. Quinidine-induced livedo reticularis.
|
Arch Dermatol
|
1989
|
0.75
|